Drug Ther Bull. 2018 Jul;56(7):78-80. doi: 10.1136/dtb.2018.7.0645.
Tight glycaemic control is key to reducing the risk of cardiovascular and microvascular complications in people with type 1 diabetes. Standard treatment involves optimising insulin therapy to achieve an HbA level of 48mmol/mol (6.5%) or lower. Although not licensed for use in type 1 diabetes, metformin is included in some clinical guidelines as adjuvant therapy for people with type 1 diabetes who are overweight and wish to improve glycaemic control while minimising the dose of insulin. The REMOVAL study is the largest trial to date that has investigated the longer-term effects of metformin in people with type 1 diabetes. Here, we consider the role of metformin in individuals with type 1 diabetes in light of these results and other study findings.
严格控制血糖是降低1型糖尿病患者心血管和微血管并发症风险的关键。标准治疗包括优化胰岛素治疗，以使糖化血红蛋白（HbA）水平达到48mmol/mol（6.5%）或更低。尽管二甲双胍未被批准用于1型糖尿病，但在一些临床指南中，它被纳入作为超重且希望在尽量减少胰岛素剂量的同时改善血糖控制的1型糖尿病患者的辅助治疗。“REMOVAL研究”是迄今为止调查二甲双胍对1型糖尿病患者长期影响的最大规模试验。在此，我们根据这些结果和其他研究发现来探讨二甲双胍在1型糖尿病患者中的作用。
